AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis
- PMID: 34670044
- DOI: 10.1056/NEJMoa2034279
AQP1 Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis
Abstract
Background: Variability in ultrafiltration influences prescriptions and outcomes in patients with kidney failure who are treated with peritoneal dialysis. Variants in AQP1, the gene that encodes the archetypal water channel aquaporin-1, may contribute to that variability.
Methods: We gathered clinical and genetic data from 1851 patients treated with peritoneal dialysis in seven cohorts to determine whether AQP1 variants were associated with peritoneal ultrafiltration and with a risk of the composite of death or technique failure (i.e., transfer to hemodialysis). We performed studies in cells, mouse models, and samples obtained from humans to characterize an AQP1 variant and investigate mitigation strategies.
Results: The common AQP1 promoter variant rs2075574 was associated with peritoneal ultrafiltration. Carriers of the TT genotype at rs2075574 (10 to 16% of patients) had a lower mean (±SD) net ultrafiltration level than carriers of the CC genotype (35 to 47% of patients), both in the discovery phase (506±237 ml vs. 626±283 ml, P = 0.007) and in the validation phase (368±603 ml vs. 563±641 ml, P = 0.003). After a mean follow-up of 944 days, 139 of 898 patients (15%) had died and 280 (31%) had been transferred to hemodialysis. TT carriers had a higher risk of the composite of death or technique failure than CC carriers (adjusted hazard ratio, 1.70; 95% confidence interval [CI], 1.24 to 2.33; P = 0.001), as well as a higher risk of death from any cause (24% vs. 15%, P = 0.03). In mechanistic studies, the rs2075574 risk variant was associated with decreases in AQP1 promoter activity, aquaporin-1 expression, and glucose-driven osmotic water transport. The use of a colloid osmotic agent mitigated the effects of the risk variant.
Conclusions: A common variant in AQP1 was associated with decreased ultrafiltration and an increased risk of death or technique failure among patients treated with peritoneal dialysis. (Funded by the Swiss National Science Foundation and others.).
Copyright © 2021 Massachusetts Medical Society.
Comment in
-
Aquaporin-1 Expression and Ultrafiltration of the Peritoneal Membrane.N Engl J Med. 2021 Oct 21;385(17):1617-1619. doi: 10.1056/NEJMe2114645. N Engl J Med. 2021. PMID: 34670049 No abstract available.
-
An AQP1 variant is associated with peritoneal dialysis outcomes.Nat Rev Nephrol. 2022 Feb;18(2):71. doi: 10.1038/s41581-021-00517-0. Nat Rev Nephrol. 2022. PMID: 34824466 No abstract available.
-
Aquaporin-1 variants: a step further towards precise prescription in peritoneal dialysis?Kidney Int. 2022 Mar;101(3):445-447. doi: 10.1016/j.kint.2021.12.022. Epub 2022 Jan 4. Kidney Int. 2022. PMID: 34990699 No abstract available.
-
Aquaporin 1 Promoter Variants in Peritoneal Dialysis: Large Insights Into Ultrasmall Pores.Am J Kidney Dis. 2022 May;79(5):757-759. doi: 10.1053/j.ajkd.2022.01.420. Epub 2022 Feb 4. Am J Kidney Dis. 2022. PMID: 35131330 No abstract available.
-
AQP1 Promoter Variant, Water Transport, and Outcome in Peritoneal Dialysis.N Engl J Med. 2022 Mar 17;386(11):1096. doi: 10.1056/NEJMc2118244. N Engl J Med. 2022. PMID: 35294824 No abstract available.
-
AQP1 Promoter Variant, Water Transport, and Outcome in Peritoneal Dialysis.N Engl J Med. 2022 Mar 17;386(11):1096-1098. doi: 10.1056/NEJMc2118244. N Engl J Med. 2022. PMID: 35294825 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
